Finding a Gap: Achieving Good Response Rates in Difficult Tumor Types
- How do established payloads compare in their ability to drive meaningful clinical responses?
- Have historically pursued targets lacked sufficient expression or accessibility to enable effective tumor penetration?
- What role can mechanisms play in increasing efficacy?